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Abstract
Background
Defective cellular transport processes can lead to aberrant accumulation of trace elements,
iron, small molecules and hormones in the cell, which in turn may promote the formation of
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reactive oxygen species, promoting DNA damage and aberrant expression of key regula-
tory cancer genes. As DNA damage and uncontrolled proliferation are hallmarks of cancer,
including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the
cellular transport genes contributes to EOC risk.
Methods
In total, DNA samples were obtained from 14,525 case subjects with invasive EOC and
from 23,447 controls from 43 sites in the Ovarian Cancer Association Consortium (OCAC).
Two hundred seventy nine SNPs, representing 131 genes, were genotyped using an Illu-
mina Infinium iSelect BeadChip as part of the Collaborative Oncological Gene-environment
Study (COGS). SNP analyses were conducted using unconditional logistic regression
under a log-additive model, and the FDR q<0.2 was applied to adjust for multiple
comparisons.
Results
The most significant evidence of an association for all invasive cancers combined and for
the serous subtype was observed for SNP rs17216603 in the iron transporter gene HEPH
(invasive: OR = 0.85, P = 0.00026; serous: OR = 0.81, P = 0.00020); this SNP was also
associated with the borderline/low malignant potential (LMP) tumors (P = 0.021). Other
genes significantly associated with EOC histological subtypes (p<0.05) included the
UGT1A (endometrioid), SLC25A45 (mucinous), SLC39A11 (low malignant potential), and
SERPINA7 (clear cell carcinoma). In addition, 1785 SNPs in six genes (HEPH,MGST1,
SERPINA, SLC25A45, SLC39A11 and UGT1A) were imputed from the 1000 Genomes
Project and examined for association with INV EOC in white-European subjects. The most
significant imputed SNP was rs117729793 in SLC39A11 (per allele, OR = 2.55, 95% CI =
1.5-4.35, p = 5.66x10-4).
Conclusion
These results, generated on a large cohort of women, revealed associations between inher-
ited cellular transport gene variants and risk of EOC histologic subtypes.
Introduction
Epithelial ovarian carcinoma (EOC) is the second-most common gynecological malignancy
and the leading cause of gynecological cancer-related mortality in the United States and other
developed nations [1]. Early stage EOC is accompanied by vague, non-specific symptoms and
is difficult to detect. As yet, no EOC screening or early detection strategies have been proven
useful in general population [2]. As a consequence, approximately 60% of cases are diagnosed
at advanced stages (III-IV), with 5-year overall survival of less than 20% [3]. Given these grim
statistics, improved understanding of the etiology of EOC is critical to reducing the associated
morbidity and mortality.
An inadequate understanding of genetic and biological etiology of EOC has limited the abil-
ity to detect and treat this disease effectively. Disruptions in cellular transport, lead to abnormal
levels of trace elements (iron, zinc and copper), hormones and small molecules which impact
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the expression of key regulatory genes. Aberrant expression of transmembrane transport genes
has been associated with increased risk, as well as aggressiveness, of a number of cancers
including breast [4–7], prostate [8], liver [9], colorectal and colon [10–12], thyroid [13] and
neuroblastoma [14]. Iron is essential for erythropoiesis [15] and the function of the mitochon-
drial respiratory chain where it plays a key role in electron transport, in the form of iron-sul-
phur clusters or in heme centers [16]. However, excess iron and copper have been reported to
promote the formation of reactive oxygen species (ROS) which damage cellular DNA and sup-
port cancer growth [17]. Hydrogen peroxide generated as a byproduct in the mitochondrial
respiratory chain, can react with iron or copper and form hydroxyl radicals that are extremely
reactive and damaging to the genome [18]. Consistent with these data, transport of the three
most abundant transition metals in humans–iron, zinc and copper–has been linked to the eti-
ology of colorectal and liver cancer [9,19] and prostate cancer [20].
Despite the growing evidence that cellular transport processes influence cancer risk, the
association of germline genetic variation in cellular transport genes and EOC risk has not been
well studied. As histologic subtypes of EOC differ in clinical behavior and biologic and genetic
origin [21], we hypothesized that single nucleotide polymorphisms (SNPs) in cellular transport
genes are associated with EOC risk and vary by histopathology. This study examined the asso-
ciation of 279 SNPs in 131 cellular transport genes and EOC risk in an international collabora-
tion that included 18,174 case and 26,134 control subjects.
Materials and Methods
Sample and Procedure
The discovery set included DNA samples from 3,761 EOC case subjects and 2,722 control sub-
jects in two ovarian cancer Genome Wide Association Studies (GWAS) in North America and
the United Kingdom (UK). Details of these studies have been previously published [22]. In
brief, the North American study was comprised of four case-control studies genotyped using
the Illumina 610-quad Beadchip Array (1,814 case subjects and 1,867 control subjects) as well
as a single case-control study genotyped on the Illumina 317K and 370K arrays (133 case sub-
jects and 142 control subjects). The UK study was comprised of four case-only studies geno-
typed on the Illumina 610-quad Beadchip Array and two common control sets genotyped on
the Illumina 550K array (1,814 case subjects and 713 control subjects).
The replication sample consisted of DNA samples from 14,525 women with invasive EOC
and 23,447 control women with European ancestry from 43 sites in the Ovarian Cancer Associ-
ation Consortium (OCAC). Samples from an additional 1,747 participants with tumors of low
malignant potential were also analyzed. Details of the sample QC are provided in Pharoah
et al., [22]. This replication set include 89 SER cases and 200 controls of African ancestry, and
249 SER cases and 1574 controls of Asian ancestry.
All research involving human participants has been approved by each study site’s local Insti-
tutional Review Board (IRB) according to the principles expressed in the Declaration of Hel-
sinki. Written informed consent was obtained from all of the participants. The permission to
use of the data in this study was granted by the University of South Florida (IRB#:
Pro00000249).
Gene and SNP Selection
Gene (NCBI) [23], BioCarta [24], GenomeNet [25] and other relevant gene/pathway databases
were used to select the candidate genes for inclusion in the transport pathway. Specifically, the
search yielded 131 genes involved in transport of trace elements, ions, hormones and small
molecules. A total of 5202 SNPs in the selected genes were identified from the Human-610
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Quad BeadChip (Illumina). Those SNPs were genotyped in the four ovarian cancer GWAS
studies (US GWAS, UK GWAS, COGS and Mayo clinic). The final selection of transport gene
SNPs for genotyping in the replication stage was informed according to lowest p-values (cut off
p<0.01 was used) by ranking of minimal p-values across four sets of results in the discovery
set: 1) North American all histologies, 2) North American serous histology, 3) combined
GWAS meta-analysis all histologies, and 4) combined GWAS meta-analysis serous histology.
Additional functional SNPs in these genes were also included. In total 299 SNPs were included
on the COGS chip of which 279 SNPs (in 131 genes) passed QC (described in detail in Pharoah
et al., [22]).
Imputation Analyses
These analyses were based on imputed genotypes from the four ovarian cancer GWAS studies
(US GWAS, UK GWAS, COGS and Mayo clinic) with a total of 15,398 invasive EOC case sub-
jects and 30,816 control subjects of white-European ancestry. Imputation of each dataset into
the 1000 Genomes Project was performed using IMPUTE2 software [26]. We used the 1000
Genomes Project v3 as the reference with pre-phasing of the data using SHAPEIT [27].
Statistical Analysis
For the discovery set, the North American and UK studies were analyzed separately and four
sets of results: 1) North American all histologies, 2) North American serous histology, 3) com-
bined GWAS meta-analysis all histologies, and 4) combined GWAS meta-analysis serous his-
tology were conducted. SNP analyses were performed using unconditional logistic regression
under a log-additive model. The last two sets were analyzed using the fixed effects meta-analy-
sis. These analyses were carried out in PLINK [28] by combining results across studies by using
the Mantel–Haenszel method [29].
For the replication set, demographic and clinical characteristics of case subjects and control
subjects were compared using t-test for continuous variables and chi-square test for categorical
variables. Unconditional logistic regression was used to evaluate associations between SNPs
and ovarian cancer risk. SNPs were modeled using number of minor alleles as ordinal variables
(log-additive model). Per-allele log odds ratios and their 95% confidence intervals were esti-
mated. All analyses were done separately by race groups.
In order to adjust for population substructure, intercontinental ancestry was assigned based
on genotype frequencies for European, Asian, and African populations using LAMP software
[30] Subjects with greater than 90 percent European ancestry were defined as European; those
with greater than 80 percent Asian and African ancestry were defined as being Asian and
African, respectively. The set of 37,000 unlinked markers was applied to perform principal-
components analysis within each major population subgroup [31].The number of principal
components was based on the inflection position of the principal components scree plot. The
models for white-European subjects were adjusted for study site and for the first five principal
components. For the African American (AA) and Asian (AS) study subjects, the first one and
five principal components were included in the models, respectively.
We evaluated associations between candidate SNPs and risk of all invasive EOC (INV), each
of the four main histological subtypes (serous (SER); endometroid (END); clear cell (CC); and
mucinous (MUC)), and tumors of low malignant potential (LMP). Odds ratios for each histo-
logic subtype were estimated by comparing cases of each subtype to all controls as reference.
False discovery rate (FDR) q-value was applied for adjusting multiple comparisons [32]. Asso-
ciations with a p value< .05 and a false discovery rate (FDR) q-value< .20 were considered
statistically significant.
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For the imputation set analyses, the meta-analysis using an in-house program written in C+
+ was carried out for combining results across studies. A fixed effect meta-analysis was used,
with the log odds ratio being the estimate for each study and the standard error of this estimate
determining the weighting. For each SNP, only the studies with valid estimates for that SNP
(i.e. r2> 0.25) were used in the meta-analysis calculation.
Results
Sample characteristics are described in the S1 Table. As expected, significant differences were
observed between case and control subjects on EOC risk factors including age, family history
of ovarian cancer, age at menarche, body mass index (BMI), history of oral contraceptive use,
and number of full term births (p-values<0.05). The proportion of tumors of SER (57.6%) was
higher than that of other subtypes (14.2% END, 7.1% CC, 6.5% MUC, and 14.6% other), which
is typical for white-European populations.
Among the 279 cellular transport SNPs genotyped in the replication set, 81 SNPs in 48
genes showed nominally significant (p<0.05) associations with at least one histological subtype
(S2 Table). All invasive cancers combined (INV), LMP and the four main histological subtypes
(SER [n = 8,369]; END [n = 2,067]; CC [n = 1,024]; and MUC [n = 943]) were analyzed.
The strongest evidence of an association for INV EOC was observed for SNP rs17216603 in
the iron transporter geneHEPH (OR = 0.85, 95%CI = 0.77–0.93, P = 2.55x10-4; FDR q-
value = 0.065), which was also the most significant SNP associated with SER (P = 1.99x10-4;
95%CI = 0.73–0.91, FDR q-value = 0.054), and LMP subtypes (P = 0.0206) (Table 1). The most
Table 1. The most significant SNPs in the transport pathway genes and risk of EOC by histology, invasiveness, and race/ethnicity1.
GENE SNP INV LMP SER CC END MUC Asian
(SER)
African-
American
(SER)
HEPHrs17216603 0.85 (0.77–
0.93); 2.55x10-4;
q = 0.063
0.78 (0.63–
0.97);
0.021;
0.81 (0.73–
0.91); 1.99x10-4;
q = 0.054
0.77 (0.58–
1.02); 0.07
0.9 (0.74–
1.08); 0.26
0.92 (0.7–
1.21); 0.56
1.45
(1.15–
1.83)
0.0019
0.76 (0.15–
3.86); 0.74
SLC39A11rs9908917 0.95 (0.92–
0.99); 0.014
0.85 (0.77–
0.93);
3.9x10-4
0.94 (0.9–0.99);
0.010
1.01 (0.91–
1.13); 0.82
0.94 (0.87–
1.02); 0.16
0.98
(0.87–
1.00); 0.7
1.25
(1.01–
1.56);
0.049
1.23 (0.85–
1.77); 0.27
SERPINA7Rs1804495 1.05 (1.00–1.1);
0.042
1.14 (1.03–
1.27); 0.016
1.06 (1.00–
1.12); 0.045
1.21 (1.06–
1.39);
0.0042
1.06 (0.96–
1.17); 0.28
0.85
(0.73–
1.00);
0.045
0.81 (0.65–
1.00); 0.05
1.11 (0.75–
1.65); 0.6
SLC25A45Rs681309 0.97 (0.94–
1.00); 0.029
1.04 (0.97–
1.12); 0.27
1 (0.96–1.04);
0.99
0.98 (0.89–
1.07); 0.59
0.91 (0.85–
0.97); 0.0035
0.89
(0.81–
0.97);
0.012
0.78
(0.63–
0.98);
0.033
0.87 (0.6–
1.26); 0.41
UGT1A Rs11563251 0.95 (0.91–1.00);
0.05
1.08 (0.96–
1.2); 0.21
0.95 (0.89–1.01);
0.07
1.03 (0.89–
1.18); 0.73
0.82 (0.74–
0.92); 6.8x10-
4; q = 0.18
1.06
(0.91–
1.22); 0.49
0.73 (0.5–
1.06); 0.1
1.22 (0.85–
1.25); 0.28
MGST1 Rs6488840 0.96 (0.93–
1.00); 0.048
1.0 (0.92–
1.09); 0.9
0.95 (0.91–
1.00); 0.042
0.96 (0.86–
1.07); 0.41
1 (0.92–1.08);
0.95
0.96
(0.86–
1.08); 0.48
0.54
(0.25–
1.18); 0.12
0.55 (0.37–
0.82); 0.0035
1 INV: all invasive EOC combined; LMP: low malignant potential / borderline tumors; SER: serous; CC: clear cell; End: endometrioid; Muc: mucinous.
Statistically signiﬁcant associations are indicated in bold (P<0.05). Data format is the following: OR (95% CI); p-value; FDR q-value (white-European
women). Only signiﬁcant FDRs (q<0.2) are shown (HEPH: INV and SER; UGT1A: End).
doi:10.1371/journal.pone.0128106.t001
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significant association for END EOC was rs11563251 within the UGT1A gene cluster
(OR = 0.82, 95%CI = 0.73–0.92, P = 6.59x10-4; FDR q-value = 0.177). Only these two SNPs
were associated with q-values<0.20. The most significant association for MUC subtype was
rs681309, near the SLC25A45 gene (OR = 0.89, 95%CI = 0.81–0.97, P = 0.012). This SNP was
also associated with the END subtype (P = 0.0035) and INV EOC (P = 0.029). Association with
rs9908917, in the intron of SLC39A11, was observed for LMP cases (OR = 0.85, 95%CI = 0.77–
0.93, P = 3.9x10-4). This SNP was also associated with the SER subtype (P = 0.0123) and INV
EOC (P = 0.0144). The SNP rs1804495 in SERPINA7 was associated with SER, MUC, CC, INV
and LMP (P<0.05), but not END (P>0.05).
Imputed Variants
In total, 1785 imputed SNPs in six genes (HEPH,MGST1, SERPINA, SLC25A45, SLC39A11
and UGT1A) were examined for association with INV EOC in white-European subjects only.
From these, 274 SNPs were found with p-value<0.05 (S3 Table). Across all six genes, the most
significant imputed SNP was rs117729793 in SLC39A11 (per allele, OR = 2.55, 95% CI = 1.5–
4.35, p = 5.66x10-4). Interestingly, 190 of 274 (~70%) imputed SNPs with p-values< 0.05 were
located in or near SLC39A11.
Results in women of African-American (AA) and Asian (AS) ethnicities
We conducted exploratory analyses for other ethnicities and SER EOC. Fourteen SNPs showed
significant associations in AS and AA women. Six of the SNPs in the AS women were also sig-
nificant in the white-European women, compared to two of the 14 SNPs in the AA women.
The top SNP in women of Asian ancestry (rs17216603 inHEPH) was shared with the white-
European women. The SLC25A45 rs681309 was also shared. SERPINA7 rs1804495 was border-
line significant (P = 0.0503), perhaps due to a small sample size. The most significant associa-
tion in women of AA ancestry was noted at the SNP rs6488840 near to the microsomal
glutathione S-transferase 1 (MGST1) gene. In our study,MGST1 rs6488840 was associated
with statistically significantly reduced SER EOC risk in women of AA ancestry (OR = 0.55;
P = 0.0035). This SNP was of borderline significance in women of white-European (OR = 0.95;
P = 0.042), but not Asian (P>0.05), ancestry. In the groups of AS and AA women, no SNPs
had FDR q-value<0.20. Results for the top hits across women of different ancestries are pre-
sented in Table 2.
Table 2. Top SNPs associated with SER EOC across racial groups.
Race White-European Asian African American
GENE SNP MAF1 p-value2 OR (95% CI)3 MAF1 p-value2 OR (95% CI) 3 MAF1 p-value2 OR (95% CI) 3
HEPH rs17216603 A = 0.03 2x10-4 0.81 (0.73–0.91) A<0.01 0.002 1.45 (1.15–1.83) A<0.01 0.74 0.76 (0.15–3.86)
SLC39A11 rs9908917 T = 0.13 0.010 0.94 (0.9–0.99) T = 0.2 0.049 1.25 (1.0–1.56) T<0.01 0.27 1.2 (0.85–1.78)
SERPINA7 rs1804495 A = 0.12 0.045 1.06 (1–1.12) A = 0.23 0.050 0.8 (0.65–1.0) A = 0.1 0.60 1.1 (0.75–1.65)
SLC25A45 rs681309 G = 0.49 0.990 1 (0.96–1.04); G = 0.26 0.033 0.78 (0.63–0.98) G = 0.1 0.41 0.8 (0.57–1.26)
UGT1A rs11563251 T = 0.12 0.074 0.95 (0.89–1.01) T = 0.07 0.100 0.7 (0.5–1.06) T = 0.42 0.281 1.2 (0.85–1.75)
MGST1 rs6488840 C = 0.2 0.042 0.95 (0.91–1) A = 0.42 0.121 0.54 (0.25–1.18) C = 0.35 0.004 0.55 (0.37–0.82)
1 MAF, minor allele and its frequency
2 p-value <0.05 are in bold
3 Odds ratio, 95% conﬁdence interval
doi:10.1371/journal.pone.0128106.t002
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Discussion
The development and progression of ovarian cancer is accompanied by aberrant cellular
metabolism [33]. Central to cellular metabolic processes are the transport of trace elements
and hormones through cellular and nuclear membranes. In this study, we aimed to elucidate
whether germline SNPs in cellular transport genes were associated with EOC risk and histo-
pathologic subtype. We detected nominal associations (P<0.05) with 81 SNPs and EOC risk
in at least one of the histopathologic subtypes (S3 Table). Associations were noted with
rs17216603 in HEPH and SER, INV and LMP subgroups as well as in SER and INV cases in
women of white-European and Asian ancestries. The Hephaestin (HEPH) gene encodes a
transmembrane copper-dependent ferroxidase (HEPH protein) responsible for dietary iron
transport from intestinal enterocytes into the blood stream [34–36].HEPH catalyzes ferrous
(F2+) iron reoxidation to its ferric (F3+) state [37–38] that can be utilized by the body. The role
of iron homeostasis in cancer progression is yet to be fully understood; however depletion of
iron stores in cells induces cell cycle arrest and apoptosis, limits the rate of DNA synthesis, and
down-regulates expression of various potentially carcinogenic kinases such as cyclins and
cyclin-dependent kinases [39]. Additionally, iron is known to facilitate generation of muta-
genic reactive oxygen species (ROS) that may drive cancer development and progression [40]
as has been observed in colorectal cancer [41]. In silico analysis ofHEPH rs17216603 combin-
ing results from Snpnexus, SNPinfo and Annovar [42–44] showed that this variant results in
the substitution of Alanine at residue 598 with Threonine and may lead to reduction or loss of
HEPH function. Functional analyses of this SNP and gene will be needed to clarify the impact
of this finding. There was no evidence of MAF heterogeneity because the MAF range of
rs17216603 across the studies is 2–5%. This SNP was significantly associated with Invasive
EOC risk in women of white-European descent (P = 0.0003) for the combined results (Fig 1).
The SNP rs9908917 lies within an intron of the SLC39A11 gene, and was associated with
SER, all INV and LMP EOC. In addition, of the 1785 SNPs in six genes (HEPH,MGST1, SER-
PINA, SLC25A45, SLC39A11 and UGT1A) imputed from the 1000 Genomes Project and exam-
ined for association with INV EOC in white-European subjects, the most significant imputed
SNP was rs117729793 in SLC39A11 (per allele, OR = 2.55, 95% CI = 1.5–4.35, p = 5.66x10-4).
In The Cancer Genome Atlas (TCGA) data [45], expression of SLC39A11 was significantly
higher in ovarian tumors compared to normal tissues (P = 9.99x10-8). Taken together, these
data highlight a potential role for this gene in EOC pathogenesis. The solute carrier family 39,
member 11 (SLC39A11) is a poorly studied gene belonging to a family of metal ion transport-
ers. SLC39A11may act as a zinc-influx transporter, although the exact functions of the A11
gene have yet to be experimentally established [46]. Other members of the SLC39 family trans-
port metal ions, such as iron, copper, cadmium and manganese [47].
SNP rs681309, in the intergenic region near SLC25A45, showed significant associations
with all INV, MUC, and END and was the most significant SNP among the MUC subtype. The
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 45
(SLC25A45) belongs to the family of membrane proteins that catalyze the transport of solutes
across the inner mitochondrial membrane [48]. While substrates for the SLC25 family carriers
include ADP/ATP, amino acids, malate, ornithine, and citruline [49], the predominant sub-
strate(s) for SLC23A45 have not yet been characterized [50], although sequence similarity to
SLC25A29 suggests that this protein may be involved in the transport of long-chain fatty acids
such as palmitoylcarnitine and acylcarnitine [51]. SLC25A45 is expressed in skeletal muscle,
intestine, brain, and testis and is downregulated during ovarian cancer progression [50]. Taken
together, these data suggest that additional studies are warranted on the role of SLC25A4 in
particular, as well as mitochondria in general, in EOC etiology.
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The SNP, rs1804495 in SERPINA7 was associated with all INV, SER, MUC, CC and LMP
subtypes, and was the most statistically significant association among the CC subtype. The ser-
pin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7 (SERPINA7),
also known as thyroxine-binding globulin (TBG), is a protein that binds thyroid hormones
thyroxin (T4) and 3,5,3’-triiodothyronine (T3) in circulation [52]. Numerous mutations in
SERPINA7 have been identified [53–54] leading to partially or completely absent TBG func-
tion. The hallmark of TBG deficiency is abnormally low T3 and T4 combined with normal thy-
roid stimulating hormone (TSH) values [55]. The specific role of SERPINA7 in cancer etiology
has not been established; however, thyroid hormones may support cancer growth [56]. Thus, it
is conceivable that altered TBG production over many years may modulate growth of early-
stage ovarian cancer cells. The index SNP, rs1804495, is coding, but the resulting missense
change is predicted to have neutral impact on the protein function, suggesting a linked variant
may be the causal allele at this locus. We note that in our analyses, rs1804495 confers statisti-
cally significantly increased risk for LMP, INV, SER and CC, but decreased risk for mucinous
EOC. This observation highlights observations from previously published studies that reveal
differences between MUC and other EOCs [57–59].
Fig 1. Forest plot forHEPH rs17216603 across studies. Squares represent the estimated per-allele odds
ratio (OR) for each study. Lines indicate the 95% confidence intervals. Diamond represents the OR estimate
and confidence limits. Invasive EOC risk in women of white-European descent only; MAF in controls.
doi:10.1371/journal.pone.0128106.g001
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The most significant association among the END subtype was with UGT1A1 rs11563251.
UDP glucuronosyltransferase 1 family, polypeptide A cluster (UGT1A) represents a complex
locus which encodes nine human UDP-glucuronosyltransferases. UDP-glucuronosyltransfer-
ase (UGT) enzymes are localized to endoplasmic reticulum (ER) and catalyze glucuronidation,
which is involved in the elimination of bilirubin, steroids, bile acids, toxic dietary components,
and several drugs, including morphine, and irinotecan [60–61]. Genetic variation in UGT1A1
is involved in inherited disorders of bilirubin metabolism such as Crigler-Najjar syndrome,
which is manifested in complete absence (type 1) or diminished (types 2–3) bilirubin glucuro-
nidation and resulting impaired bilirubin excretion. Previously, the UGT1A73 allele exhibited
modestly significant association with colorectal cancer (OR = 2.39; P = 0.02) [57], lung cancer
[62], endometrial cancer [63] and pancreatic cancer (OR = 1.98; P = 0.003) [64] with a particu-
larly strong association in smokers with pancreatic carcinoma who were younger than 55 years
(OR = 4.7; P = 0.0009), suggesting the magnitude of the observed associations may be modified
by environmental interactions. Down-regulation of UGT1A appears to be an early event in car-
cinogenesis [65]; it is postulated that constitutive expression of UGT1A family genes in normal
mucosa protects organs from carcinogens released in the bladder or absorbed from the diet in
the colon. The rs11563251 variant lies within the 3’UTR of the UGT1A1,-A6 and–A10 genes,
and so could feasibly impact the RNA stability of these transcripts. Alternatively, since this
SNP also lies within intronic sequences of other UGT1A genes, this SNP could possibly be
involved in cis-regulation of expression of one or more genes in this cluster.
In this study we conducted exploratory analyses in AS and AA subjects. However, the
power to detect associations in women of non-European ancestries was limited due to small
sample size and only the SER subtype of EOC was investigated for risk associations. The top
SNPs in the AS ancestry group (rs17216603 inHEPH and rs1552846 in SLC39A11) were also
significant in white-European women. In women of AA ancestry, the most significant SNP
rs6488840 (P = 0.0035) was close to the microsomal glutathione S-transferase 1 (MGST1) gene,
which encodes a protein that catalyzes the conjugation of glutathione to electrophiles and the
reduction of lipid hydroperoxides. This protein is localized to the endoplasmic reticulum and
outer mitochondrial membrane where it is thought to protect these membranes from oxidative
stress. The product of this gene is involved in cellular defenses against toxic, carcinogenic, and
pharmacologically active electrophilic compounds [66].MGST1 overexpression has been dem-
onstrated in various cancers (e.g., prostate cancer and lung cancer [67–68]) and has been asso-
ciated with high metastatic potential and chemoresistance [69].MGST1 is abundantly
expressed in EOC primary tumors, metastases and effusions [66]. Other significant SNPs in
women of AA ancestry include various members of the SLC39 family: SLC39A11 (rs9905659
and rs16977431) and SLC39A8 (rs233807).
The main strength of our study is a large sample size of white-European women that
afforded sufficient statistical power to detect modest risk differences. Weaknesses, however,
include the lack of functional or metabolic studies to establish biological significance of the
observed associations. Another weakness is a small sample size in AA and AS women. The con-
tribution of genetic and/or biological differences to EOC among different ethnic groups is
unclear. However, because ovarian cancer health disparities are observed along the whole con-
tinuum of the disease globally and in the U.S. [70], this topic is without a doubt important and
deserves its own dedicated studies.
In summary, we have found that genetic variation in transmembrane transport genes appear
to be associated with EOC risk across various histologic subtypes (Table 1). These data suggest
that disruptions in cellular transport (trace elements, hormones and small molecules) may play
roles in EOC pathogenesis. Functional and metabolic studies are needed to support these
findings.
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EKA XQ YYT HSLJ ZC AYC JPW KA HAC NA FB HB EVB YTB MWBMB LB NB LAB
ABW CHB RB IC KC JCC PJC LSK DWC JMC CC ADMAdB EDicks EDespierre JAD TD
MD DFE DME RPE ABE PAF BLF YTG AGMGGG RGMTG JG PHarrington PHA AH FH
MATH PHarter CKH EH SH AJakubowska AJensen BTJ BYK LEKMK LAK CK SKK JLAK
CK SKKJ JK DLambrechts SLambrechts NDL AWL SLele AL JLubinski DAL DLiang BKL JLis-
sowska KLMatsuo LJ LL LFAGM KMVMG JRM IMN UM RLM FM KBM LN RBN HN SN
KO SHO IO SO RPW JP CLP TP LMPMCP EMP HAR BRMAR JHR AR IBR IKR HBS ES IS
XOS YBS NSWS HSMCS LS SHT KLT PJT ILT AT SST AMvA RAV IV CSW SWG NW
ASW KGW LRW AHWXW YLWHYWZ AZ HNH AB GCT ESI JMS SJR ELG ANAM SAG
SAN TAS PDPP CMP. Wrote the paper: GC HYL JPT KLu JD EKA XQ YYT HSLJ ZC AYC
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JPW KA HAC NA FB HB EVB YTB MWBMB LB NB LAB ABW CHB RB IC KC JCC PJC
LSK DWC JMC CC ADMAdB EDicks EDespierre JAD TDMD DFE DME RPE ABE PAF
BLF YTG AGM GGG RGMTG JG PHarrington PHA AH FHMATH PHarter CKH EH SH
AJakubowska AJensen BTJ BYK LEKMK LAK CK SKK JLAK CK SKKJ JK DLambrechts
SLambrechts NDL AWL SLele AL JLubinski DAL DLiang BKL JLissowska KLMatsuo LJ LL
LFAGM KMVMG JRM IMN UM RLM FM KBM LN RBN HN SN KO SHO IO SO RPW JP
CLP TP LMPMCP EMP HAR BR MAR JHR AR IBR IKR HBS ES IS XOS YBS NSWS HS
MCS LS SHT KLT PJT ILT AT SST AMvA RAV IV CSW SWG NWASW KGW LRWAHW
XW YLWHYWZ AZ HNH AB GCT ESI JMS SJR ELG ANAM SAG SAN TAS PDPP CMP.
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